Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study

[1] Cross M(2014)The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study Ann Rheum Dis 73 1323-1330

[2] Smith E(2020)2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee Arthritis Rheum 72 220-233

[3] Hoy D(2018)EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis Ann Rheum Dis 77 797-807

[4] Nolte S(2019)OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis Osteoarthr Cartil 27 1578-1589

[5] Ackerman I(2018)Opioids for chronic noncancer pain: a systematic review and meta-analysis JAMA. 320 2448-2460

[6] Fransen M(2019)Trends in prescription analgesic use among adults with musculoskeletal conditions in the United States, 1999-2016 JAMA Netw Open 2 e1917228-2220

[7] Kolasinski SL(2019)Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety Pain. 160 2210-17

[8] Neogi T(2015)A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee Osteoarthr Cartil 23 S8-461

[9] Hochberg MC(2001)The Western Ontario and McMaster universities osteoarthritis index (WOMAC): a review of its utility and measurement properties Arthritis Care Res 45 453-158

[10] Oatis C(2001)Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain. 94 149-121

[1] Cross M(2014)The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study Ann Rheum Dis 73 1323-1330

[2] Smith E(2020)2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee Arthritis Rheum 72 220-233

[3] Hoy D(2018)EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis Ann Rheum Dis 77 797-807

[4] Nolte S(2019)OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis Osteoarthr Cartil 27 1578-1589

[5] Ackerman I(2018)Opioids for chronic noncancer pain: a systematic review and meta-analysis JAMA. 320 2448-2460

[6] Fransen M(2019)Trends in prescription analgesic use among adults with musculoskeletal conditions in the United States, 1999-2016 JAMA Netw Open 2 e1917228-2220

[7] Kolasinski SL(2019)Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety Pain. 160 2210-17

[8] Neogi T(2015)A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee Osteoarthr Cartil 23 S8-461

[9] Hochberg MC(2001)The Western Ontario and McMaster universities osteoarthritis index (WOMAC): a review of its utility and measurement properties Arthritis Care Res 45 453-158

[10] Oatis C(2001)Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain. 94 149-121